Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health News of Alabama.
Press releases published on May 14, 2025
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
GlobeNewswire
·
May 14, 2025
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary …
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
GlobeNewswire
·
May 14, 2025
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven …
Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors
GlobeNewswire
·
May 14, 2025
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of …
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
GlobeNewswire
·
May 14, 2025
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical …
Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.
GlobeNewswire
·
May 14, 2025
BOWIE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Internationally acclaimed neurologist and epilepsy researcher Dr. Orrin Devinsky will be honored with the Lifetime Accelerator Award during the Epilepsy Therapies …
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered …
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
GlobeNewswire
·
May 14, 2025
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first …
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
GlobeNewswire
·
May 14, 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an …
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
GlobeNewswire
·
May 14, 2025
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, …
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
GlobeNewswire
·
May 14, 2025
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for …
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
GlobeNewswire
·
May 14, 2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary …
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
·
May 14, 2025
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann …
A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients
GlobeNewswire
·
May 14, 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified …
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
GlobeNewswire
·
May 14, 2025
FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its …
HEKA AI Mattress Named “Best Overall SleepTech Solution” in 2025 MedTech Breakthrough Awards Program
GlobeNewswire
·
May 14, 2025
LOS ANGELES, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market, today …
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
GlobeNewswire
·
May 14, 2025
NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- …
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
GlobeNewswire
·
May 14, 2025
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate …
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewswire
·
May 14, 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing …
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
GlobeNewswire
·
May 14, 2025
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE …